{"product_id":"amgn-bcg-matrix","title":"Amgen Inc. (AMGN): BCG Matrix [June-2026 Updated]","description":"\u003cp\u003eGet a ready-made, research-based BCG Matrix Analysis of Amgen Inc. Business that maps Stars like Repatha ($876M, +34%), Evenity ($562M, +27%), and Uplizna (+188%) against Cash Cows such as Enbrel ($320M) and Amgen's $8.62B Q1 2026 revenue base, while also assessing Question Marks like MariTide, Imdylltra, Tepezza, and Blinatumomab, and Dogs such as Prolia ($727M, -34%) and Xgeva ($447M, -20%). It helps you quickly understand portfolio balance, market growth, relative market share, and where capital is being directed through R\u0026amp;D, dividends, and expansion decisions for coursework, essays, case studies, presentations, or business research.\u003c\/p\u003e\u003ch2\u003eAmgen Inc. - BCG Matrix Analysis: Stars\u003c\/h2\u003e\n\n\u003cp\u003eAmgen's Star businesses are the growth engines combining strong market position with high expansion rates. In the BCG Matrix, these are the products and franchises that are not only scaling quickly but are also establishing or defending leadership in large, commercially important markets. For Amgen, the clearest Star assets in Q1 2026 were Repatha, EVENITY, UPLIZNA, and the broader growth-driver portfolio that sustained companywide momentum.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRepatha acceleration\u003c\/strong\u003e stands out as one of Amgen's strongest Star performers. Repatha generated $876 million in Q1 2026 sales, increasing 34% year over year, while volume rose 44%. That spread between volume growth and sales growth indicates broad demand expansion rather than price-driven performance. Repatha is also part of Amgen's six key growth drivers, which together accounted for 70% of total product sales in the quarter. This strength helped Amgen post Q1 2026 revenue of $8.62 billion, up 6% year over year, and non-GAAP EPS of $5.15, both ahead of expectations. Amgen's raised full-year 2026 revenue guidance of $37.1 billion to $38.5 billion further reinforces Repatha's position as a Star asset with meaningful scale and continued upside.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eStar Asset\u003c\/th\u003e\n\u003cth\u003eQ1 2026 Sales\u003c\/th\u003e\n\u003cth\u003eYear-over-Year Growth\u003c\/th\u003e\n\u003cth\u003eKey Signal\u003c\/th\u003e\n\u003cth\u003eBCG Interpretation\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepatha\u003c\/td\u003e\n\u003ctd\u003e$876 million\u003c\/td\u003e\n\u003ctd\u003e34%\u003c\/td\u003e\n\u003ctd\u003eVolume grew 44%\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEVENITY\u003c\/td\u003e\n\u003ctd\u003e$562 million\u003c\/td\u003e\n\u003ctd\u003e27%\u003c\/td\u003e\n\u003ctd\u003eMarket share leadership maintained\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUPLIZNA\u003c\/td\u003e\n\u003ctd\u003e$262 million\u003c\/td\u003e\n\u003ctd\u003e188%\u003c\/td\u003e\n\u003ctd\u003eEU marketing authorization for NMOSD\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth driver portfolio\u003c\/td\u003e\n\u003ctd\u003e70% of product sales contribution\u003c\/td\u003e\n\u003ctd\u003e6% company revenue growth\u003c\/td\u003e\n\u003ctd\u003e16 brands with double-digit growth\u003c\/td\u003e\n\u003ctd\u003eStar engine\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eEVENITY leadership\u003c\/strong\u003e is another clear Star within Amgen's portfolio. EVENITY sales rose 27% year over year to $562 million in Q1 2026, supported by market share leadership in bone-building therapeutics. Leadership matters in a fast-growing category because it signals durable competitive strength, not just temporary momentum. EVENITY also sits among the six growth drivers that generated 70% of product sales, showing its importance to Amgen's earnings mix. With FY2025 revenue up 10% to $36.75 billion and Q1 2026 non-GAAP EPS at $5.15, EVENITY contributes to a high-growth profile that fits the Star quadrant.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eQ1 2026 sales reached $562 million.\u003c\/li\u003e\n\u003cli\u003eSales growth was 27% year over year.\u003c\/li\u003e\n\u003cli\u003eManagement confirmed market share leadership in bone-building therapeutics.\u003c\/li\u003e\n \u003cli\u003eIncluded in the six growth drivers responsible for 70% of product sales.\u003c\/li\u003e\n \u003cli\u003eSupports Amgen's scalable growth profile alongside rising profitability.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eUPLIZNA surge\u003c\/strong\u003e represents a high-growth rare disease franchise with expanding commercial potential. Q1 2026 sales surged 188% to $262 million, making it one of Amgen's fastest-growing products. A major catalyst came on June 1, 2026, when the European Commission granted marketing authorization for NMOSD, broadening the product's addressable market. UPLIZNA entered Amgen through the Horizon Therapeutics acquisition and now serves as an important rare disease platform within the company. Its momentum is further supported by Amgen's elevated R\u0026amp;D investment, which rose 16% to $1.7 billion across 273 active clinical trials in Q1 2026. Strong growth, new approvals, and pipeline backing place UPLIZNA firmly in the Star category.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe growth driver portfolio\u003c\/strong\u003e is itself a Star-like engine because it combines scale, breadth, and continued expansion. Amgen reported that 16 brands delivered double-digit sales growth in Q1 2026, underscoring how diversified the company's growth profile has become. The six key growth drivers-Repatha, EVENITY, Tezspire, rare disease, innovative oncology, and biosimilars-contributed 70% of total product sales. That concentration shows these franchises are not peripheral; they are the main force behind company performance. They helped push Q1 revenue to $8.62 billion and supported the upgraded 2026 revenue guidance range of $37.1 billion to $38.5 billion after FY2025 revenue of $36.75 billion.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e16 brands delivered double-digit sales growth in Q1 2026.\u003c\/li\u003e\n \u003cli\u003eSix key growth drivers contributed 70% of product sales.\u003c\/li\u003e\n \u003cli\u003eRevenue increased to $8.62 billion in Q1 2026.\u003c\/li\u003e\n \u003cli\u003eFY2025 revenue reached $36.75 billion, up 10%.\u003c\/li\u003e\n \u003cli\u003eFull-year 2026 revenue guidance was raised to $37.1 billion to $38.5 billion.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eWithin the BCG framework, Amgen's Stars are defined by their ability to grow fast while holding strong competitive positions in large addressable markets. Repatha delivers powerful demand-led growth, EVENITY combines share leadership with robust sales expansion, UPLIZNA shows exceptional acceleration from a rare disease base, and the broader growth-driver portfolio provides the scale and consistency needed to sustain enterprise growth. These businesses are central to Amgen's current market strength and remain the main contributors to revenue expansion, margin support, and forward guidance confidence.\u003c\/p\u003e\u003ch2\u003eAmgen Inc. - BCG Matrix Analysis: Cash Cows\u003c\/h2\u003e\n\n\u003cp\u003eEnbrel remains one of Amgen's clearest Cash Cows. In Q1 2026, the product delivered $320 million in sales despite a 37% year-over-year decline, with pressure coming from lower net selling price and inventory fluctuations rather than an immediate patent cliff. The US District Court for the Eastern District of Virginia dismissed Sandoz's antitrust suit, and Amgen's patent position is protected through 2029. That gives Enbrel continued monetization value even as growth matures.\u003c\/p\u003e\n\n\u003cp\u003eThe commercial logic is straightforward: Enbrel is established, large, and still cash-generative. While the product is no longer a growth engine, it continues to produce meaningful revenue that supports Amgen's broader portfolio. Its durability helps finance quarterly R\u0026amp;D spending of $1.7 billion and supports the company's $2.52 per share dividend. In BCG terms, Enbrel fits the Cash Cow profile because it operates in a low-growth segment but retains strong market value and contribution to corporate cash flow.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCash Cow Indicator\u003c\/th\u003e\n\u003cth\u003eAmgen Data\u003c\/th\u003e\n\u003cth\u003eImplication\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnbrel Q1 2026 sales\u003c\/td\u003e\n\u003ctd\u003e$320 million\u003c\/td\u003e\n\u003ctd\u003eLarge legacy product still generating cash\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYear-over-year change\u003c\/td\u003e\n\u003ctd\u003e-37%\u003c\/td\u003e\n\u003ctd\u003ePressure from pricing and inventory, not immediate patent loss\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent protection\u003c\/td\u003e\n\u003ctd\u003eThrough 2029\u003c\/td\u003e\n\u003ctd\u003eExtends monetization runway\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuarterly R\u0026amp;D spending\u003c\/td\u003e\n\u003ctd\u003e$1.7 billion\u003c\/td\u003e\n\u003ctd\u003eCash cows help fund pipeline investment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuarterly dividend\u003c\/td\u003e\n\u003ctd\u003e$2.52 per share\u003c\/td\u003e\n\u003ctd\u003eSupports shareholder returns\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eAmgen's broader financial base also reinforces its Cash Cow status. The company generated $8.62 billion of Q1 2026 revenue and $5.15 of non-GAAP EPS. Free cash flow increased to $1.5 billion from $1.0 billion in the prior-year quarter, showing that the business is still producing strong cash conversion even while investing heavily. These results point to a mature commercial platform that continues to fund both operations and strategic expansion.\u003c\/p\u003e\n\n\u003cp\u003eFY2025 further confirms the stability of the base. Revenue reached $36.75 billion, product sales totaled $35.15 billion, and GAAP operating income was $9.1 billion with a 25.8% margin. A 10% revenue increase in FY2025 shows that the portfolio still has resilience, even without relying on high-growth categories alone. This is the behavior expected from a Cash Cow: steady earnings, strong margins, and dependable cash generation.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eQ1 2026 revenue: $8.62 billion\u003c\/li\u003e\n\u003cli\u003eQ1 2026 non-GAAP EPS: $5.15\u003c\/li\u003e\n\u003cli\u003eQ1 2026 free cash flow: $1.5 billion\u003c\/li\u003e\n\u003cli\u003eFY2025 revenue: $36.75 billion\u003c\/li\u003e\n\u003cli\u003eFY2025 product sales: $35.15 billion\u003c\/li\u003e\n\u003cli\u003eFY2025 GAAP operating income: $9.1 billion\u003c\/li\u003e\n \u003cli\u003eFY2025 GAAP operating margin: 25.8%\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eCapital return is another defining element of Amgen's Cash Cow profile. In Q1 2026, the dividend increased 6% to $2.52 per share, reflecting confidence in ongoing cash generation. The company also raised its 2026 revenue guidance to $37.1 billion to $38.5 billion after a strong quarter. Even with R\u0026amp;D up 16% to $1.7 billion, Amgen still produced $1.5 billion in free cash flow, showing that the mature base is sufficiently strong to support both reinvestment and distributions.\u003c\/p\u003e\n\n\u003cp\u003eAmgen's cash engine is also being reinforced through disciplined capital deployment. The company announced an additional $300 million investment in U.S. manufacturing on top of nearly $2 billion committed over the prior year. This combination of operating cash flow, dividend growth, and capacity expansion is characteristic of a Cash Cow business unit: it generates surplus cash while remaining strategically important to the company's long-term structure.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCapital Allocation Metric\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eCash Cow Effect\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2026 revenue guidance\u003c\/td\u003e\n\u003ctd\u003e$37.1 billion to $38.5 billion\u003c\/td\u003e\n\u003ctd\u003eSignals confidence in sustained cash generation\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2026 R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$1.7 billion\u003c\/td\u003e\n\u003ctd\u003eFunds future growth without weakening the base\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2026 free cash flow\u003c\/td\u003e\n\u003ctd\u003e$1.5 billion\u003c\/td\u003e\n\u003ctd\u003eProvides funding for dividends and investment\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDividend growth\u003c\/td\u003e\n\u003ctd\u003e6%\u003c\/td\u003e\n\u003ctd\u003eReturns cash to shareholders\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdditional U.S. manufacturing investment\u003c\/td\u003e\n \u003ctd\u003e$300 million\u003c\/td\u003e\n\u003ctd\u003eUses cash to strengthen operating capacity\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecent manufacturing commitments\u003c\/td\u003e\n\u003ctd\u003eNearly $2 billion\u003c\/td\u003e\n\u003ctd\u003eShows disciplined reinvestment from a strong base\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe Cash Cow character of Amgen's business is most visible in the way mature products, especially Enbrel, continue to support the company's financial structure. Even with revenue pressure in certain legacy areas, Amgen's scale, margins, dividend capacity, and free cash flow show a business that reliably converts market position into cash. That cash then sustains the R\u0026amp;D engine, manufacturing expansion, and shareholder distributions that support the rest of the portfolio.\u003c\/p\u003e\n\u003ch2\u003eAmgen Inc. - BCG Matrix Analysis: Question Marks\u003c\/h2\u003e\n\n\u003cp\u003eAmgen's Question Marks are concentrated in assets with meaningful clinical upside, but limited or no current sales contribution. These programs sit in high-growth therapeutic spaces where commercial scale is still being built, while the company continues to fund development across its 273 active clinical trials and a Q1 2026 R\u0026amp;D run rate of $1.7 billion. The common pattern is clear: strong data, low monetization, and a path that depends on execution, timing, and market adoption.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eCurrent Stage\u003c\/th\u003e\n\u003cth\u003eKey 2026 Milestone\u003c\/th\u003e\n\u003cth\u003eCommercial Status\u003c\/th\u003e\n\u003cth\u003eBCG Classification\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMariTide\u003c\/td\u003e\n\u003ctd\u003ePrecommercial\u003c\/td\u003e\n\u003ctd\u003eMARITIME-SWITCH Phase 3 started May 1, 2026\u003c\/td\u003e\n \u003ctd\u003eNo reported product revenue as of June 2026\u003c\/td\u003e\n \u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIMDYLLTRA\u003c\/td\u003e\n\u003ctd\u003eLaunched in Europe\u003c\/td\u003e\n\u003ctd\u003eEuropean Commission approval on June 1, 2026\u003c\/td\u003e\n \u003ctd\u003eSales not disclosed in latest update\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTEPEZZA subcutaneous formulation\u003c\/td\u003e\n\u003ctd\u003ePost-positive study\u003c\/td\u003e\n\u003ctd\u003ePositive results reported April 30, 2026\u003c\/td\u003e\n \u003ctd\u003eNo disclosed Q1 2026 sales for new form\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubcutaneous blinatumomab\u003c\/td\u003e\n\u003ctd\u003eDevelopment paused\u003c\/td\u003e\n\u003ctd\u003eEnrollment paused December 31, 2025\u003c\/td\u003e\n\u003ctd\u003eNo clear commercialization path\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eMariTide optionality\u003c\/strong\u003e is one of the clearest Question Marks in Amgen's pipeline. The asset remains precommercial, so it had no reported product revenue as of June 2026. In Phase 2, patients maintained weight loss on lower monthly or quarterly maintenance doses, with less nausea and vomiting, which supports a differentiated obesity strategy. Amgen began the MARITIME-SWITCH Phase 3 trial on May 1, 2026 to evaluate transitions from weekly GLP-1 therapy to 8-week or quarterly dosing. In a market as large and competitive as obesity, dosing convenience can be commercially important, but until launch and uptake are visible, the asset remains a classic Question Mark.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eNo reported product revenue as of June 2026\u003c\/li\u003e\n \u003cli\u003ePhase 2 data supported lower-frequency maintenance dosing\u003c\/li\u003e\n \u003cli\u003eMARITIME-SWITCH Phase 3 started on May 1, 2026\u003c\/li\u003e\n \u003cli\u003ePotentially differentiated by 8-week or quarterly dosing\u003c\/li\u003e\n \u003cli\u003eLarge obesity market creates upside, but commercialization remains unproven\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eIMDYLLTRA entry\u003c\/strong\u003e adds another high-potential but still-developing growth asset. The European Commission granted marketing authorization on June 1, 2026 for extensive-stage small cell lung cancer, following trial results showing a 40% reduction in risk of death. The product fits Amgen's innovative oncology expansion, but the latest update did not disclose sales. Since Amgen still relies on its six growth drivers for 70% of product sales, IMDYLLTRA has room to scale before it materially changes the company's revenue profile. That makes it a strong clinical story with still-uncertain financial conversion.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eEuropean Commission approval granted June 1, 2026\u003c\/li\u003e\n \u003cli\u003eIndication: extensive-stage small cell lung cancer\u003c\/li\u003e\n \u003cli\u003eTrial results showed a 40% reduction in risk of death\u003c\/li\u003e\n - \u003cli\u003eLatest update did not disclose sales\u003c\/li\u003e\n\u003cli\u003ePart of Amgen's oncology growth push\u003c\/li\u003e\n\u003cli\u003eCommercial contribution remains early relative to the company's revenue base\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eTEPEZZA formulation\u003c\/strong\u003e represents a convenience-led extension rather than a new disease-area bet. Positive results for a subcutaneous form were reported on April 30, 2026, with the goal of improving convenience in thyroid eye disease. No Q1 2026 sales were disclosed for the new formulation, so uptake, prescribing behavior, and return on investment remain uncertain. This asset is being developed in an environment of heavy innovation spending, including a 16% increase in Q1 R\u0026amp;D to $1.7 billion, backed by 273 active trials. The strategic value is visible, but the monetization curve is not yet established.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ1 2026 \/ 2026 Data\u003c\/th\u003e\n\u003cth\u003eImplication\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spending\u003c\/td\u003e\n\u003ctd\u003e$1.7 billion in Q1 2026\u003c\/td\u003e\n\u003ctd\u003eShows continued investment in pipeline expansion\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D growth\u003c\/td\u003e\n\u003ctd\u003eUp 16%\u003c\/td\u003e\n\u003ctd\u003eSupports multiple experimental and lifecycle assets\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive clinical trials\u003c\/td\u003e\n\u003ctd\u003e273\u003c\/td\u003e\n\u003ctd\u003eSignals broad innovation capacity and capital intensity\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTEPEZZA subcutaneous sales\u003c\/td\u003e\n\u003ctd\u003eNot disclosed for Q1 2026\u003c\/td\u003e\n\u003ctd\u003eCommercial traction still unproven\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eSubcutaneous blinatumomab reset\u003c\/strong\u003e is the weakest of the Question Marks because the program lost momentum. Amgen paused enrollment in the registration-enabling Phase 2 study on December 31, 2025, which suggests the pathway to commercialization is not yet clear. Even so, the company continues to support a broad innovation engine, including AI-enabled development and digital twins in rare disease studies. With 273 active clinical trials and record 2025 R\u0026amp;D spending of $7.2 billion, Amgen has the capacity to keep optionality alive. The challenge is that without resumed enrollment or a stronger development signal, the program remains stuck in a low-visibility, low-certainty position.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eEnrollment paused on December 31, 2025\u003c\/li\u003e\n\u003cli\u003ePhase 2 was registration-enabling\u003c\/li\u003e\n\u003cli\u003eNo clear commercialization timeline disclosed\u003c\/li\u003e\n \u003cli\u003eSupported by Amgen's broader digital and AI development capabilities\u003c\/li\u003e\n \u003cli\u003eDependent on future trial progress to regain momentum\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAcross these programs, the common BCG logic is the same: high-growth opportunity, limited current share of revenue, and substantial dependence on future execution. MariTide carries the largest obesity upside, IMDYLLTRA has the clearest near-term oncology validation, TEPEZZA's new formulation is a convenience upgrade with uncertain demand, and subcutaneous blinatumomab is the least advanced commercially. Together, they show how Amgen is using capital-intensive R\u0026amp;D to build future growth drivers while maintaining a diversified pipeline presence across obesity, oncology, thyroid eye disease, and hematology.\u003c\/p\u003e\u003ch2\u003eAmgen Inc. - BCG Matrix Analysis: Dogs\u003c\/h2\u003e\n\n\u003cp\u003eIn the Dog quadrant of the BCG Matrix, Amgen's portfolio includes brands that still generate meaningful revenue or cash flow, but whose growth profile is weakening under structural pressure. These assets remain economically relevant in the near term, yet their trajectory is clearly negative because of biosimilar competition, policy-driven erosion, or regulatory uncertainty. For Amgen, the issue is not only scale, but the declining ability of these products to expand relative market share in a maturing or shrinking market.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eLatest Reported Sales\u003c\/th\u003e\n\u003cth\u003ePeriod\u003c\/th\u003e\n\u003cth\u003eChange\u003c\/th\u003e\n\u003cth\u003ePrimary Pressure\u003c\/th\u003e\n\u003cth\u003eBCG Category\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProlia\u003c\/td\u003e\n\u003ctd\u003e$727 million\u003c\/td\u003e\n\u003ctd\u003eQ1 2026\u003c\/td\u003e\n\u003ctd\u003e-34%\u003c\/td\u003e\n\u003ctd\u003eBiosimilar competition in international markets\u003c\/td\u003e\n \u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXGEVA\u003c\/td\u003e\n\u003ctd\u003e$447 million\u003c\/td\u003e\n\u003ctd\u003eQ4 2025\u003c\/td\u003e\n\u003ctd\u003e-20%\u003c\/td\u003e\n\u003ctd\u003eGlobal biosimilar launches\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOtezla\u003c\/td\u003e\n\u003ctd\u003e$1.2 billion impairment charge\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003ctd\u003eWrite-down\u003c\/td\u003e\n\u003ctd\u003eMedicare price setting under the IRA\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTAVNEOS\u003c\/td\u003e\n\u003ctd\u003eNot disclosed as accelerating\u003c\/td\u003e\n\u003ctd\u003eApril 30, 2026 regulatory action\u003c\/td\u003e\n\u003ctd\u003eDownside risk\u003c\/td\u003e\n\u003ctd\u003eFDA proposed withdrawal of approval\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eProlia erosion\u003c\/strong\u003e is one of the clearest examples of a Dog within Amgen's portfolio. Prolia generated $727 million in Q1 2026 sales, but revenue fell 34% year over year. Management attributed the decline to expected biosimilar competition in international markets, which is especially important because the brand had long been one of the company's high-value bone health franchises. Even though Amgen's 2025 revenue still increased 10% to $36.75 billion, Prolia is no longer contributing as a growth engine. The quarterly decline shows that the asset remains large but is now moving under structural pressure, with the market share base becoming harder to defend.\u003c\/p\u003e\n\n\u003cp\u003eProlia's positioning fits the Dog category because the product is still monetizable, yet its market opportunity is shrinking. A 34% sales drop in one quarter is not a temporary fluctuation; it signals competitive displacement. In BCG terms, this means low growth and weakening relative strength. Amgen can still extract revenue from the brand, but the economics are being progressively squeezed by biosimilars, making reinvestment less attractive than channeling resources into newer franchises.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eXGEVA runoff\u003c\/strong\u003e follows the same pattern. XGEVA posted $447 million of sales in Q4 2025, down 20% from the prior period. Management expects accelerated erosion in 2026 as multiple global biosimilar launches reach the market. That outlook places the brand in a harvest phase rather than an expansion phase. The product can still contribute cash to the broader company, especially given Amgen's $9.1 billion of operating income in 2025 and a 25.8% operating margin, but the trajectory is clearly downward. A mature product with declining sales and rising biosimilar exposure belongs in the Dog quadrant.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eQ4 2025 XGEVA sales: $447 million\u003c\/li\u003e\n\u003cli\u003eYear-over-year decline: 20%\u003c\/li\u003e\n\u003cli\u003e2026 outlook: accelerated erosion from multiple biosimilar launches\u003c\/li\u003e\n \u003cli\u003eRole in portfolio: cash contribution, not growth contribution\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eXGEVA's Dog classification is reinforced by the timing of biosimilar entry. Once competitive alternatives proliferate globally, pricing power tends to weaken quickly, and market share becomes increasingly difficult to protect. For a company with strong margins, a declining product can still be acceptable as a cash generator, but it does not merit aggressive growth investment. The brand's shrinking sales base and visible runoff are consistent with a mature franchise entering decline.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOtezla impairment\u003c\/strong\u003e adds another Dog-like signal, not through sales collapse alone, but through economic destruction. Amgen recorded a $1.2 billion intangible asset impairment charge for Otezla in 2025. The write-down followed Otezla's selection for Medicare price setting under the Inflation Reduction Act, which directly reduces expected future value. That accounting action shows the franchise has already lost momentum rather than gaining it. Although Amgen's FY2025 revenue still rose 10% to $36.75 billion, Otezla was not one of the six growth drivers that supplied 70% of product sales. The asset is therefore mature, policy pressured, and capital destructive.\u003c\/p\u003e\n\n\u003cp\u003eOtezla's impairment matters in BCG terms because a Dog is not only a weak grower; it is also a business unit whose future returns may no longer justify the capital tied to it. The $1.2 billion charge reflects a revised valuation premise, not just softer demand. When a brand is re-priced downward by policy and no longer anchors growth, it becomes harder to defend as a strategic investment. In practical terms, Otezla is now more of a cash and accounting burden than a platform for expansion.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eTAVNEOS threat\u003c\/strong\u003e is the most acute Dog risk among the four. The FDA proposed withdrawing approval of TAVNEOS on April 30, 2026 because of effectiveness concerns. That action introduces immediate downside risk to the rare disease portfolio and places the product in a vulnerable position. Unlike Amgen's growth drivers, TAVNEOS has no disclosed sales acceleration in the latest update. With the company still spending $1.7 billion per quarter on R\u0026amp;D and expanding manufacturing by another $300 million, capital allocation becomes critical, and a product facing possible removal from the market is difficult to justify as a priority.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eFDA action date: April 30, 2026\u003c\/li\u003e\n\u003cli\u003eReason: effectiveness concerns\u003c\/li\u003e\n\u003cli\u003ePortfolio impact: immediate regulatory downside risk\u003c\/li\u003e\n \u003cli\u003eCapital context: $1.7 billion quarterly R\u0026amp;D spend and $300 million manufacturing expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eTAVNEOS fits the Dog quadrant because its risk profile is not simply slow growth; it is existential uncertainty. A product under possible withdrawal lacks the visibility needed for sustained reinvestment. In a portfolio where Amgen is already supporting high-cost innovation and manufacturing expansion, resources directed toward a threatened asset are less efficient than resources directed toward scalable growth drivers. The combination of regulatory pressure and absent growth data makes TAVNEOS an especially weak strategic candidate.\u003c\/p\u003e\n\n\u003cp\u003eAcross these Dog assets, the pattern is consistent: mature revenue base, visible erosion, and limited upside relative to the capital required to defend them. Prolia and XGEVA are both facing biosimilar pressure, Otezla has already suffered a major impairment, and TAVNEOS faces regulatory uncertainty. Together, they show how a strong company can still carry declining brands that consume managerial attention while contributing diminishing strategic value.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44601010520213,"sku":"amgn-bcg-matrix","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/amgn-bcg-matrix.png?v=1740145936","url":"https:\/\/dcf-analysis.com\/products\/amgn-bcg-matrix","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}